Showing 5021-5030 of 7244 results for "".
- Recurrence in Patients with Thin Melanomas Linked with Poor Prognosis, Despite Rarityhttps://practicaldermatology.com/news/recurrence-patients-thin-melanomas-linked-poor-prognosis-despite-rarity/2467070/While rare, the recurrence of melanomas in patients with thin melanomas was linked with poorer prognosis and lower survival rates, a single-center analysis reported. "The majority of patients diagnosed with melanoma have thin melanomas (≤1 mm)," the researchers wrote in their study, publi
- FDA Approves New Tralokinumab-ldrm Autoinjectorhttps://practicaldermatology.com/news/fda-approves-new-tralokinumab-ldrm-autoinjector/2467047/The US Food and Drug Administration (FDA) announced the approval of a new tralokinumab-ldrm 300-mg single-dose autoinjector for adult patients. Adbry® (LEO Pharma Inc.), a high-affinity fully human monoclonal antibody, is currently indicated in the US for the treatment of moderate-to-sever
- Study: Upadacitinib Produces Sustained Improvements in 140 Weekshttps://practicaldermatology.com/news/study-upadacitinib-produces-sustained-improvements-140-weeks/2467045/Patients with moderate-to-severe atopic dermatitis (AD) experienced sustained improvements in skin signs/symptoms through 140 weeks while receiving upadacitinib and rates of long-term patient-related outcome improvements were numerically higher with upadacitinib 30 mg compared with upadacitinib 1
- FDA Approves Adbry Autoinjector for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis (AD)https://practicaldermatology.com/news/fda-approves-adbry-autoinjector-treatment-adults-moderate-severe-atopic-dermatitis-ad/2467043/The FDA has approved LEO Pharma's Adbry (tralokinumab-ldrm) 300 mg single-dose autoinjector for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older.1 The new autoinjector (300 mg/2 mL) will provide another option for adult patients in addit
- Moderate-to-Severe AA Linked to AD Comorbidityhttps://practicaldermatology.com/news/moderate-severe-aa-linked-ad-comorbidity/2467042/Patients with moderate-to-severe alopecia areata (AA) had higher prevalence and incidence of atopic dermatitis (AD) comorbidity and higher prevalence of moderate-to-severe AD than those with mild AA in a study presented this month at the Revolutionizing Alopecia, Vitligo, and Eczema (RAVE) Confer
- Suntegrity Recalls Multiple Lots of Sunscreen Foundationhttps://practicaldermatology.com/news/suntegrity-recalls-multiple-lots-sunscreen-foundation/2467041/Suntegrity Skincare has announced that it is recalling nine lots of Suntegrity Impeccable Skin Sunscreen Foundation (Multiple Shades) due to the discovery of a higher-than-acceptable microbiological mold count (Aspergillus sydowii), according to an FDA alert. According to the man
- Adtralza Pre-Filled Pen Now Available for Canadian Atopic Dermatitis Patientshttps://practicaldermatology.com/news/adtralza-pre-filled-pen-now-available-canadian-atopic-dermatitis-patients/2467019/A new Adtralza® (tralokinumab injection) pre-filled pen has been made available for the first time in Canada for the treatment of moderate-to-severe atopic dermatitis (AD), according to a press announcement from LEO Pharma Inc. The single-use 2 mL pre-filled pen "simplifies the
- FDA Gives Green Light to InnoCare's Clinical Trial of TYK2 Inhibitor ICP-332 for ADhttps://practicaldermatology.com/news/fda-gives-green-light-innocares-clinical-trial-tyk2-inhibitor-icp-332-ad/2467004/InnoCare Pharma announced that the FDA has cleared its investigational new drug (IND) application for its novel TYK2 (Tyrosine Kinase 2) inhibitor, ICP-332. ICP-332 is a potent and selective TYK2 inhibitor. It achieved multiple efficacy endpoints in the China phase 2 study for the treatmen
- Parental E-Cigarette Use Linked to Pediatric ADhttps://practicaldermatology.com/news/parental-e-cigarette-use-linked-pediatric-ad/2467003/Electronic cigarette use by parents is associated with increased chances of pediatric atopic dermatitis, according to an article published last month by JAMA Dermatology. In a retrospective cross-sectional analysis of the 2014 to 2018 National Health Interview Survey, researchers found tha
- FDA Takes Key Step on Tapinarof for ADhttps://practicaldermatology.com/news/fda-takes-key-step-tapinarof-ad/2467002/The US Food and Drug Administration has accepted a supplemental new drug application for Dermavant’s VTAMA (tapinarof) following positive results of a Phase III clinical trial for the drug’s use on atopic dermatitis patients 2 and older, according to GlobalData. Tapinarof, an aryl hydrocar